Search Results 241-250 of 17237 for Proto-oncogene
[ALK]/ c-ros oncogene 1 [ROS1]) per National Comprehensive Cancer Network (NCCN) guidelines, participant has also been previously treated with or is ...
An additional validated oncogenic driver in MTC if known that could cause resistance to selpercatinib treatment. Examples include, but are not limited to ...
Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who ...
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
Four cores in the Mayo Clinic Ovarian Cancer SPORE provide vital help with administration, clinical trials, biospecimens, statistics and research models.
Studying samples of tissue, blood, and urine in the laboratory from patients receiving CYP-17 inhibition therapy may help doctors learn more about changes that ...
This study is being performed to understand the causes of drug resistance and to improve the treatment options for patients diagnosed with B-cell cancers.
A recent Mayo Clinic study demonstrated that endoscopic ultrasound-acquired cytology-based tumor genotyping can reveal a spectrum of genetic variants, ...
The purpose of this study is to evaluate the efficacy and the safety/tolerability of poziotinib in patients with NSCLC exon 20 insertion mutations.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.